^
    5d
    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer (clinicaltrials.gov)
    P2, N=26, Completed, Samsung Medical Center | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    5d
    Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. (PubMed, Jpn J Clin Oncol)
    Prior ICI exposure may not significantly affect the efficacy or safety of subsequent taxane plus RAM therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab) • oxaliplatin
    7d
    Lung-MAP Sub-Study: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)
    8d
    Acclaim-2: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Genprex, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab) • Reqorsa (quaratusugene ozeplasmid)
    14d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=592, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    16d
    A Case of Recurrent Esophagogastric Junction Cancer with Long‒Term Complete Response by Trastuzumab Deruxtecan (PubMed, Gan To Kagaku Ryoho)
    After neoadjuvant chemotherapy (docetaxel +oxaliplatin + S-1: DOS), he underwent proximal gastrectomy, double tract reconstruction and para-aortic lymph node dissection...In November 2021, the patient presented with para-aortic lymph node recurrence and was treated with S-1 + oxaliplatin (SOX) + trastuzumab (Tmab) and paclitaxel + ramucirumab, but the lymph nodes were enlarged and trastuzumab deruxtecan (T-DXd) therapy was started...T-DXd was approved for the treatment of HER2-positive unresectable advanced or recurrent gastric cancer from the 6th edition of Gastric Cancer Treatment Guidelines. We report a case of long-term CR maintenance after T-DXd therapy for recurrent esophagogastric junction gastric cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • docetaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    19d
    REVIVE: A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, University of Chicago
    New P2 trial • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc)
    19d
    Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Fox Chase Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab)
    21d
    Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial. (PubMed, Target Oncol)
    RAS mutations in ctDNA and elevated IL-8 levels prior to second-line FOLFIRI plus RAM were associated with worse prognosis in mCRC. Moreover, our study demonstrated a significant association between RAS mutations and high IL-8 levels in this setting, suggesting a potential molecular-inflammatory interplay that contributes to resistance to VEGFR2 blockade.
    Clinical data • Journal
    |
    KDR (Kinase insert domain receptor) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • RAS (Rat Sarcoma Virus)
    |
    RAS mutation • RAS wild-type
    |
    5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    22d
    Five years after IMbrave150 with clinical integration of atezolizumab plus bevacizumab in hepatocellular carcinoma. (PubMed, Ann Hepatol)
    After progression on ate/bev, evidence across cohorts favors tyrosine kinase inhibitor strategies such as lenvatinib over sorafenib. Cabozantinib and ramucirumab (for alpha-fetoprotein ≥400 ng/mL) are options and selected patients may benefit from immune checkpoint inhibitor-based combinations...Although ate/bev has improved outcomes in uHCC, key gaps remain, including biomarkers for regimen selection, de-escalation criteria, optimal sequencing, and integration with LRT or perioperative care. Prospective studies are needed to guide practice.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab)
    23d
    Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Northwestern University
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • Cyramza (ramucirumab) • Lytgobi (futibatinib)
    23d
    Lung-MAP Non-Match Sub-Study: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2/3, N=82, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Feb 2027 --> Jun 2027
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets)